Announced Fri, 11 Sept, 2026 · 08:44 IST
Glenmark Pharma bank loan rating upgraded to IND AA+ with Stable outlook
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹2415.00
prior close
₹2411.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.4-0.4-1.0-1.8-0.2-0.2-0.2+1.8+2.5-4.3———
Up moveDown movePending
AI summary
India Ratings upgraded Glenmark Pharma long-term bank loan rating from IND AA to IND AA+ with a Stable outlook. Short-term rating affirmed at IND A1+. Total bank loan facilities rated at about INR 42,000 million. Upgrade reflects about USD 560 million already recognized in FY26 from AbbVie licensing deal for ISB 2001, with about USD 70 million each likely in FY27 and FY28. Company is at net cash position with zero gross debt at end FY26.
Likely market impact
Positive for shareholders, signals stronger balance sheet, net cash position, and reduced financial risk after the AbbVie deal.